-
Mashup Score: 18
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Source: www.onclive.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 18
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Source: www.onclive.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 38Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases - 9 day(s) ago
Lurbinectedin was evaluated in a multicenter, open-label, Basket phase 2 study in nine cohorts of patients with different difficult-to-treat tumor types to establish the proof of concept for clinical development [1–5]. Based on the results observed in a cohort of 105 patients with pretreated small cell lung cancer (SCLC) [1], lurbinectedin was approved first in the United States [6] and later in several other countries worldwide. Furthermore, and based on these same results, the European Society of Medical Oncology (ESMO) and the US National Comprehensive Cancer Network (NCCN) guidelines incorporated lurbinectedin as an option for the second-line treatment of SCLC patients [7,8].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 59
Precision oncology requires additional predictive biomarkers for targeted therapy selection. Variant allele frequency (VAF), measuring the proportion of variant alleles within a genomic locus, provides insights into tumor clonality in somatic genomic testing, yielding a strong rationale for targeting dominant cancer cell populations. The prognostic and predictive roles of VAF have been evaluated across different studies. Yet, the absence of validated VAF thresholds and a lack of standardization between sequencing assays currently hampers its clinical utility. Therefore, analytical and clinical validation must be further examined. This Review summarizes the evidence regarding the use of VAF as a predictive biomarker and discusses challenges and opportunities for its clinical implementation as a decision-making tool for targeted therapy selection.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20
Summary:. Liquid biopsies are emerging as powerful minimally invasive approaches that have the potential to solve several long-standing problems spanning the continuum of cancer care: early detection of cancer, minimal residual disease tracking, and refinement of the heterogeneity of clinical responses together with therapeutic response monitoring in the metastatic setting. Existing challenges driven by technical limitations and establishment of the clinical value of liquid biopsies represent fields of active research that call for convergence science approaches to bridge scientific discovery with clinical care.
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study - 10 day(s) ago
PURPOSE Outcomes for Richter transformation (RT) are poor with current therapies. The efficacy and safety of anti-CD19 chimeric antigen receptor T-cell therapy (CAR-T) for RT are not established. METHODS We performed an international multicenter retrospective study of patients with RT who received CAR-T. Patient, disease, and treatment characteristics were summarized using descriptive statistics, and modeling analyses were used to determine association with progression-free survival (PFS) and overall survival (OS). PFS and OS were estimated from the date of CAR-T infusion. RESULTS Sixty-nine patients were identified. The median age at CAR-T infusion was 64 years (range, 27-80). Patients had a median of four (range, 1-15) previous lines of therapy for CLL and/or RT, including previous Bruton tyrosine kinase inhibitor and/or BCL2 inhibitor therapy in 58 (84%) patients. The CAR-T product administered was axicabtagene ciloleucel in 44 patients (64%), tisagenlecleucel in 17 patients (25%),
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 13
Nature Medicine – In a case series of six patients with multidrug-resistant rheumatoid arthritis, the CD19xCD3-targeting bispecific T cell engager blinatumomab reduced disease activity and led to…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5
PURPOSE Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer with genomic alterations known to be drug targets. Results of a cohort of patients with solid tumors with BRAF alterations treated with regorafenib are reported. METHODS Eligible patients had measurable disease (RECIST v.1.1), Eastern Cooperative Oncology Group performance status 0-1, adequate organ function, and no standard treatment options. The primary end point was disease control (DC), defined as investigator assessment of patients with complete or partial response (PR) or stable disease of at least 16-weeks duration (SD16+). Low accruing histology-specific cohorts with BRAF alterations treated with regorafenib were collapsed into a single histology-pooled cohort for this analysis. The results were evaluated on the basis of a one-sided exact binomial test with a null DC rate of 15% versus 3
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Targeting All BRAF Alterations: The (Re)-Search Continues - 10 day(s) ago
VivekSubbiah & colleagues delve into the @ASCO #TAPURStudy, shedding light on the importance of targeting ALL #BRAFAlterations, beyond V600E. (Re)-search continues, urging us to push the boundaries and unlock new possibilities in #PrecisionMedicine. #CancerResearch #JCOPO
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8VA expands 'Close to Me' cancer program, bringing cancer diagnosis and treatment closer to thousands of Veterans - 10 day(s) ago
As a part of the Biden Cancer Moonshot, the Department of Veterans Affairs is expanding its Close to Me cancer care program.
Source: news.va.govCategories: General Medicine News, Hem/OncsTweet
Full approval 👉🏼FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer https://t.co/aA0Sl7ZknB via @onclive